Effects of Local Vibrations Program of Dorsiflexor Muscles on Neuromotor Recovery in Subacute Stroke Patients.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorCentre Hospitalier Universitaire de Saint Etienne

About this trial

The aim of the vibration intervention proposed in the current study is to allow a better neuromotor recovery in subacute stroke patients when compared with standard rehabilitation alone. These last years, it has been proven that the solicitation of a muscle using vibrations may lead to positive effects on the neuromuscular function. Thus, the aim of the current study is to assess if the addition to a standard rehabilitation program of local vibrations sessions of the dorsiflexor muscles of the paretic limb of stroke patients may allow a better recovery of walking speed (primary outcome). One group using vibrations (i.e. experimental group) and one group with sham vibration (i.e. control group) will take part to this study.

Eligibility criteria

Qualifiers

Stroke patients in subacute rehabilitation phase (between 14 days and 3 months post-stroke)

Presenting with a stroke, ischemic or hemorrhagic

Lower-limb deficiency with an initial motor testing < 4 according to the MRC scale

No neurological history with functional impact other than stroke

Disqualifiers

Multiple stroke

Other neurological, cognitive or psychiatric conditions

Orthopedic ankle history compromising measurements

Botulinum toxin injected in the lower limb prior the study protocol

Trial design

Treatments tested in this trial

  • Vibration
  • Sham vibration
  • 10 meters Walk Test
  • 2 Minute Walk Test (2MWT)
  • Fugl-Meyer (FMA-LE)
  • Modified Ashworth scale
  • ABILOCO questionnaire
  • Barthel index
  • isometric ergometer
  • Electromyograms (EMG)
  • Traditional quantified gait analysis
  • SPM - Statistical Parametric Mapping
  • FACIT questionnaire (Functional Assessment of Chronic Illness Therapy)

Treatment groups

70 Participants
are divided into 2 treatment groups

Sponsors and collaborators